Global Cancer Diagnostics market and Drivers, Restraints, and Opportunities 2018-2024

  • Product Code:
    RP-ID-10078059
  • Published Date:
    Mar 2019
  • Region:
    Global
  • Pages:
    118
  • Category:
    Healthcare & Pharmaceuticals
  • Publisher:
    Infoholic Research
Global Cancer Diagnostics Market – Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 2018–2024
Overview: Cancer diagnostic testing involves tests and procedures that confirms the presence of disease and identify the correct tumor type, location, extent and stage which will help physician to give the appropriate treatment. Biopsy, imaging tests, nuclear medicine scans, tumor biomarker tests are some of the diagnostic tests used for cancer diagnostics. According to the estimation of National cancer institute, in US around 1.6 million new cases of cancer are diagnosed, and 595,690 people have died due to cancer in 2016. Canada has estimated 202,400 new cases of cancer and nearly 78,000 deaths according to Canadian cancer society in 2016. While in Europe, 1.3 million people were diagnosed in 2015. According to National cancer institute, nearly 60% new cases of cancer are from Asia, Africa, Central and South American countries and nearly 70% of cancer deaths are also from this region. China has witnessed 4.3 million new cases of cancer and 2.8 million deaths in 2015. According to Indian council for medical research, India accounts for 1.4 million new cases of cancer and 736,000 cancer related death in 2016.
The cancer diagnostics market is booming due to increasing incidence of cancer globally, growing elderly population across the globe, increased use of personalized medicine in clinical practice, and development of new novel technologies such as nanotechnology. However, lack of skilled labors and high cost of diagnosis are some of the factors hampering the market growth to an extent.
Market Analysis: The “Global Cancer Diagnostics Market” is estimated to witness a CAGR of 11.6% during the forecast period 2018–2024. The market is analyzed based on four segments – method of diagnosis, application, end-user and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). The North America is set to be the leading region for the cancer diagnostics market growth followed by Europe, Asia Pacific and Rest of the World.
Method of diagnosis Analysis: The global Cancer Diagnostics market by method of diagnosis is segmented into tumor biomarker tests, tissue diagnostics (biopsy), liquid biopsy, imaging, and others. Imaging occupied the largest share in 2017, and liquid biopsy is expected to grow at a high CAGR in the coming years due to high preference of molecular based non-invasive tests, and increasing adoption of personalized medicine. Imaging is further segmented into magnetic resonance imaging, computed tomography, ultrasound, mammography, and nuclear imaging.
Application Analysis: The global cancer diagnostics market by application is segmented into lung cancer, breast cancer, Colorectal cancer, prostate cancer and others. Lung cancer occupied the largest share in 2017, and breast cancer application is expected to be fastest growing segment during the forecasted period.
End-Users Analysis: The global cancer diagnostics market by end-users is segmented into Hospitals, diagnostic laboratories, academic & research institutes and others. Hospitals occupies a major share of cancer diagnostics market in 2017 and is expected to be same for next five years.
Key Players: F. Hoffmann-La Roche Ltd, Abbott Laboratories, Inc., Siemens Healthineers (Siemens AG), Thermo Fisher Scientific, Inc., GE Healthcare, Qiagen N.V., Agilent Technologies, Inc., Hologic, Inc., Koninklijke Philips N. V. and other predominate & niche players.
Competitive Analysis: Currently, the imaging dominates the global cancer diagnostics market. The existing leading players and other predominant market players are concentrating on this market to offer advanced products. The key market players are acquiring other companies to enhance their product portfolio and strengthen their leadership position in the market. Apart from this, key players are also launching new products to have edge in this market. For instance, in July 2017, the MEDITE Cancer Diagnostics, Inc., announced the launch of SureCyte C1 fluorogenic instant staining product universally. In April 2017, Roche announced the launch of anti-p504s (SP116) Rabbit Monoclonal Primary Antibody, for the diagnosis of prostate cancer.
Benefits: The report provides complete details about the usage and adoption rate of cancer diagnostics products in various applications and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, government initiatives toward the product adoption in the upcoming years along with the details of commercial products available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
Key Stakeholders:


Table of Contents
1 INDUSTRY OUTLOOK 9
1.1 Industry overview 9
1.2 Total addressable market 9
1.3 Industry Trends 10
2 Report Outline 11
2.1 Report Scope 11
2.2 Report Summary 11
2.3 Research Methodology 12
2.4 Report Assumptions 12
3 Market Snapshot 13
3.1 Market Definition – Infoholic Research 13
3.2 Advantage of cancer diagnostics 13
3.3 Disadvantage of cancer diagnostics 13
3.4 Segmented Addressable Market (SAM) 14
3.5 Trends of the cancer diagnostics market 14
3.6 Related Markets 15
3.6.1 Companion diagnostics 15
3.6.2 Genetic testing 16
3.6.3 Point-of-Care Diagnostics 16
4 Market Outlook 16
4.1 Overview 16
4.2 Funding scenario 17
4.3 Market segmentation 19
4.4 PEST Analysis 19
4.5 Porter 5(Five) Forces 20
5 Market Characteristics 22
5.1 DRO – Global Cancer Diagnostics Market Dynamics 22
5.1.1 Drivers 22
5.1.1.1 Rising incidence of cancer globally 22
5.1.1.2 Growing geriatric population 23
5.1.1.3 Growing demand of personalized medicine 23
5.1.2 Opportunities 24
5.1.2.1 Revolutionary nanotechnology in cancer diagnostics 24
5.1.2.2 Increasing medical tourism 24
5.1.3 Restraints 25
5.1.3.1 High cost of diagnosis 25
5.1.3.2 Lack of skilled professionals 25
6 Method of Diagnosis: Market Size and Analysis 28
6.1 Overview 28
6.2 Tumor biomarker tests 29
6.3 Tissue diagnostics 31
6.4 Liquid biopsy 32
6.5 Imaging 33
6.5.1 Magnetic resonance imaging (MRI) 35
6.5.2 Computed tomography (CT) 35
6.5.3 Ultrasound 35
6.5.4 Mammography 36
6.5.5 Nuclear imaging 36
6.6 Others 36
7 Application: Market Size and Analysis 37
7.1 Overview 37
7.2 Lung cancer 38
7.3 Breast cancer 39
7.4 Colorectal cancer 39
7.5 Prostate cancer 40
7.6 Others 40
8 End Users: Market Size and Analysis 41
8.1 Overview 41
8.2 Hospitals 42
8.3 Diagnostic Laboratories 42
8.4 Academic & research institutes 42
8.5 Others 43
9 Regions: Market Size and Analysis 43
9.1 Overview 43
9.2 North America 44
9.2.1 Overview 44
9.2.2 US 45
9.2.3 Canada 46
9.3 Europe 46
9.3.1 Overview 46
9.3.2 UK 47
9.3.3 Germany 47
9.3.4 France 48
9.3.5 Spain 48
9.4 APAC 48
9.4.1 Overview 48
9.4.2 India 49
9.4.3 China 50
9.5 Rest of the World 50
10 Competitive Landscape 52
10.1 Overview 52
11 Vendor Profiles 56
11.1 F.Hoffmann-La Roche Ltd 56
11.1.1 Overview 56
11.1.2 Business Unit 59
11.1.3 Geographic Presence 60
11.1.4 61
11.1.5 Business Focus 61
11.1.6 SWOT Analysis 61
11.1.7 Business Strategy 62
11.2 Abbott Laboratories 63
11.2.1 Overview 63
11.2.2 Business Unit 69
11.2.3 Geographic Presence 69
11.2.4 Business Focus 70
11.2.5 SWOT Analysis 71
11.2.6 Business Strategy 71
11.3 Siemens Healthineers (Siemens AG) 72
11.3.1 Overview 72
11.3.2 Business Units 77
11.3.3 Geographic Presence 79
11.3.4 Business Focus 79
11.3.5 SWOT Analysis 80
11.3.6 Business Strategy 80
11.4 Thermo Fisher Scientific Inc. 81
11.4.1 Overview 81
11.4.2 Geographic Presence 87
11.4.3 Business Focus 87
11.4.4 SWOT Analysis 88
11.4.5 Business Strategies 88
11.5 GE Healthcare 89
11.5.1 Overview 89
11.5.1.1 Business unit 94
11.5.1.2 Business focus 95
11.5.1.3 SWOT analysis 95
11.5.2 Business Strategy 96
12 Companies to Watch For 97
12.1 Qiagen N.V. 97
12.1.1 Overview 97
12.2 BioMerieux S.A. 100
12.2.1 Overview 100
12.2.2 BioMerieux S.A.: Recent Developments 101
12.3 Agilent Technologies, Inc 102
12.3.1 Overview 102
12.3.2 Agilent Technologies: Recent Developments 103
12.4 Becton Dickinson and Company 105
12.4.1 Overview 105
12.4.2 Becton dickenson and company: Recent Developments 105
12.5 Hologic Inc. 106
12.5.1 Overview 106
12.5.2 Hologic Inc.: Recent Developments 106
12.6 Illumina, Inc. 108
12.6.1 Overview 108
12.6.2 Illumina Inc.: Recent Developments 109
12.7 Koninklijke Philips N.V. 112
12.7.1 Overview 112
12.7.2 Koninklijke Philips N.V.: Recent Developments 114
13 Annexure 116
13.1 Abbreviations 116

Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report
F. Hoffmann-La Roche Ltd, Abbott Laboratories, Inc., Siemens Healthineers (Siemens AG), Thermo Fisher Scientific, Inc., GE Healthcare, Qiagen N.V., Agilent Technologies, Inc., Hologic, Inc., Koninklijke Philips N. V. and other predominate & niche players
Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Related Reports